+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Dilated Cardiomyopathy Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030

  • PDF Icon

    Report

  • 118 Pages
  • August 2022
  • Region: Global
  • Acute Market Reports
  • ID: 5713549
Description Jump to:

Industry Outlook

The dilated cardiomyopathy therapeutics market is set to reach US$ xx Mn by 2030 from US$ xx Mn in 2021 featuring magnificent growth at a compounded annual growth rate (CAGR) of 4.7% during the forecast period from 2022 to 2030. As per the latest research citings of World Health Organization (WHO), annually 17.9 million people die throughout the globe from cardiovascular diseases which is equivalent o 31% of all global deaths. Factors responsible for congestive heart failure are sedentary lifestyle, obesity, unhealthy lifestyle and congenital heart complications.

Pharmaceuticals companies are striving earnestly to manufacture drugs with least possible side effects and desired therapeutic efficacy. Drugs in Phase III clinical trials showing promising results are enalapril orodispersible minitablets (Ethicare GmbH), ARRY-371797 (Array BioPharma) and ixCELL-DCM (Vericel Corporation).

Excellent clinical outcomes and satisfactory patient compliance makes drug class the most viable treatment option for dilated cardiomyopathy

In the current scenario drug class are reigning the treatment segment for dilated cardiomyopathy therapeutics market. The parameters responsible for the growth of drug class are increasing number of patients diagnosed with congestive heart failure. Moreover excellent clinical outcomes and satisfactory patient compliance make drug class the most viable option for the treatment of dilated cardiomyopathy. Angiotensin converting enzyme inhibitors (ACE inhibitors) are considered as first line of drug therapy due to its positive clinical effects such as relaxing heart muscles and promoting blood flow. Angiotensin receptor blockers are given with diuretics to patients that do not tolerate ACE inhibitors. They help to regulate the blood flow by widening of blood vessels and reducing the fluid in lungs and kidneys. Beta blockers and anticoagulants are prescribed to reduce the pressure on the heart valves and prevent blood clotting in the heart chambers due to inability of the weakened left ventricular muscles to pump the blood. Implantable devices are gaining traction owing to the side effects associated with drug class and long term benefit provided by devices such as heart pumps, biventricular pacemakers and implantable cardioveter-defibrillators.

Rising prevalence of congestive heart failure drive the dilated cardiomyopathy therapeutics market growth in North America

North America is currently leading the geography segment for dilated cardiomyopathy therapeutics market owing to factors such as rising prevalence of congestive heart failure. According to the facts presented by Center for Disease Control and Prevention (CDC) in United States approximately 610,000 people die of heart disease annually. Existence of well-developed healthcare infrastructure and affordable reimbursement scenario drive the dilated cardiomyopathy market growth in North America. As per the latest research citings of European Heart Network (EHN) every year 3.9 million people die in Europe amounting to 45% of all deaths caused in the region. Domicile of major players such as Merck & Co., Inc., GlaxoSmithKline Plc and t2cure GmbH etc., propel the market growth in European Union region. Asia Pacific will register outstanding growth during the forecast period on account of rising prevalence of congenital heart diseases, favorable regulatory scenario and growing medical tourism due to affordable treatment cost. Latin America and Middle East & Africa serve as a potential market to promote business expansion opportunities by establishing subsidiaries and retail outlets for major players proving treatment option for dilated cardiomyopathy.

Pharmaceutical companies spearheading the dilated cardiomyopathy therapeutics market are Aastrom Biosciences, Capricor Therapeutics, GlaxoSmithkline Plc, Johnson and Johnson, Kasiak Research Pvt. Ltd., Merck & Co., Inc., MyoKardia, Pfizer, Inc., t2cure, GmbH, Teva Pharmaceutical Industries, ZensunSci & Tech.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Dilated Cardiomyopathy Therapeutics market are as follows:
  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.
  • Geographical revenues generate by countries considered in the report
  • Micro and macro environment factors that are currently influencing the Dilated Cardiomyopathy Therapeutics market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Treatment

  • Drug Class
  • Angiotensin II Receptor Blockers
  • Angiotensin-Converting Enzyme (ACE) Inhibitors
  • Beta Blockers
  • Anticoagulants
  • Digitalis
  • Diuretics
  • Implantable Device
  • Heart Pumps
  • Biventricular Pacemakers
  • Implantable Cardioverter-Defibrillators

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Dilated Cardiomyopathy Therapeutics market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Dilated Cardiomyopathy Therapeutics market?
  • Which is the largest regional market for Dilated Cardiomyopathy Therapeutics market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Dilated Cardiomyopathy Therapeutics market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Dilated Cardiomyopathy Therapeutics market worldwide?


This product will be delivered within 2 business days.

Table of Contents

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Dilated Cardiomyopathy Therapeutics Market
2.2. Global Dilated Cardiomyopathy Therapeutics Market, By Treatment, 2021 (US$ Million)
2.3. Global Dilated Cardiomyopathy Therapeutics Market, By Geography, 2021 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2021

3. Dilated Cardiomyopathy Therapeutics Market: Competitive Analysis
3.1. Market Positioning of Key Dilated Cardiomyopathy Therapeutics Market Vendors
3.2. Strategies Adopted by Dilated Cardiomyopathy Therapeutics Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2021 Versus 2030

4. Dilated Cardiomyopathy Therapeutics Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Dilated Cardiomyopathy Therapeutics Market Value, 2020 - 2030, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis

5. Dilated Cardiomyopathy Therapeutics Market: By Treatment, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
5.3.1. Drug Class
5.3.1.1. Angiotensin II Receptor Blockers
5.3.1.2. Angiotensin-Converting Enzyme (ACE) Inhibitors
5.3.1.3. Beta Blockers
5.3.1.4. Anticoagulants
5.3.1.5. Digitalis
5.3.1.6. Diuretics
5.3.2. Implantable Device
5.3.2.1. Heart Pumps
5.3.2.2. Biventricular Pacemakers
5.3.2.3. Implantable Cardioverter-Defibrillators

6. North America Dilated Cardiomyopathy Therapeutics Market, 2020-2030, USD (Million)
6.1. Market Overview
6.2. Dilated Cardiomyopathy Therapeutics Market: By Treatment, 2020-2030, USD (Million)
6.3.Dilated Cardiomyopathy Therapeutics Market: By Region, 2020-2030, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Dilated Cardiomyopathy Therapeutics Market: By Treatment, 2020-2030, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Dilated Cardiomyopathy Therapeutics Market: By Treatment, 2020-2030, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Dilated Cardiomyopathy Therapeutics Market: By Treatment, 2020-2030, USD (Million)

7. UK and European Union Dilated Cardiomyopathy Therapeutics Market, 2020-2030, USD (Million)
7.1. Market Overview
7.2. Dilated Cardiomyopathy Therapeutics Market: By Treatment, 2020-2030, USD (Million)
7.3.Dilated Cardiomyopathy Therapeutics Market: By Region, 2020-2030, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Dilated Cardiomyopathy Therapeutics Market: By Treatment, 2020-2030, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Dilated Cardiomyopathy Therapeutics Market: By Treatment, 2020-2030, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Dilated Cardiomyopathy Therapeutics Market: By Treatment, 2020-2030, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Dilated Cardiomyopathy Therapeutics Market: By Treatment, 2020-2030, USD (Million)
7.3.1.5. France
7.3.1.5.1. Dilated Cardiomyopathy Therapeutics Market: By Treatment, 2020-2030, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Dilated Cardiomyopathy Therapeutics Market: By Treatment, 2020-2030, USD (Million)

8. Asia Pacific Dilated Cardiomyopathy Therapeutics Market, 2020-2030, USD (Million)
8.1. Market Overview
8.2. Dilated Cardiomyopathy Therapeutics Market: By Treatment, 2020-2030, USD (Million)
8.3.Dilated Cardiomyopathy Therapeutics Market: By Region, 2020-2030, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Dilated Cardiomyopathy Therapeutics Market: By Treatment, 2020-2030, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Dilated Cardiomyopathy Therapeutics Market: By Treatment, 2020-2030, USD (Million)
8.3.1.3. India
8.3.1.3.1. Dilated Cardiomyopathy Therapeutics Market: By Treatment, 2020-2030, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Dilated Cardiomyopathy Therapeutics Market: By Treatment, 2020-2030, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Dilated Cardiomyopathy Therapeutics Market: By Treatment, 2020-2030, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Dilated Cardiomyopathy Therapeutics Market: By Treatment, 2020-2030, USD (Million)

9. Latin America Dilated Cardiomyopathy Therapeutics Market, 2020-2030, USD (Million)
9.1. Market Overview
9.2. Dilated Cardiomyopathy Therapeutics Market: By Treatment, 2020-2030, USD (Million)
9.3.Dilated Cardiomyopathy Therapeutics Market: By Region, 2020-2030, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Dilated Cardiomyopathy Therapeutics Market: By Treatment, 2020-2030, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Dilated Cardiomyopathy Therapeutics Market: By Treatment, 2020-2030, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Dilated Cardiomyopathy Therapeutics Market: By Treatment, 2020-2030, USD (Million)

10. Middle East and Africa Dilated Cardiomyopathy Therapeutics Market, 2020-2030, USD (Million)
10.1. Market Overview
10.2. Dilated Cardiomyopathy Therapeutics Market: By Treatment, 2020-2030, USD (Million)
10.3.Dilated Cardiomyopathy Therapeutics Market: By Region, 2020-2030, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Dilated Cardiomyopathy Therapeutics Market: By Treatment, 2020-2030, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Dilated Cardiomyopathy Therapeutics Market: By Treatment, 2020-2030, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Dilated Cardiomyopathy Therapeutics Market: By Treatment, 2020-2030, USD (Million)

11. Company Profile
11.1. Aastrom Biosciences
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Capricor Therapeutics
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. GlaxoSmithKline plc.
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Johnson and Johnson
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Kasiak Research Pvt. Ltd.
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. Merck & Co., Inc.
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. MyoKardia
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Pfizer Inc.
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. t2cure GmbH.
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Teva Pharmaceutical Industries
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives
11.11. ZensunSci & tech.
11.11.1. Company Overview
11.11.2. Financial Performance
11.11.3. Product Portfolio
11.11.4. Strategic Initiatives

List of Figures
Figure 1 Global Dilated Cardiomyopathy Therapeutics Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Dilated Cardiomyopathy Therapeutics Market: Quality Assurance
Figure 5 Global Dilated Cardiomyopathy Therapeutics Market, By Treatment, 2021
Figure 6 Global Dilated Cardiomyopathy Therapeutics Market, By Geography, 2021
Figure 7 Market Geographical Opportunity Matrix - Global Dilated Cardiomyopathy Therapeutics Market, 2021
Figure 8 Market Positioning of Key Dilated Cardiomyopathy Therapeutics Market Players, 2021
Figure 9 Global Dilated Cardiomyopathy Therapeutics Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
Figure 10 Global Dilated Cardiomyopathy Therapeutics Market, By Treatment, 2021 Vs 2030, %
Figure 11 U.S. Dilated Cardiomyopathy Therapeutics Market (US$ Million), 2020 - 2030
Figure 12 Canada Dilated Cardiomyopathy Therapeutics Market (US$ Million), 2020 - 2030
Figure 13 Rest of North America Dilated Cardiomyopathy Therapeutics Market (US$ Million), 2020 - 2030
Figure 14 UK Dilated Cardiomyopathy Therapeutics Market (US$ Million), 2020 - 2030
Figure 15 Germany Dilated Cardiomyopathy Therapeutics Market (US$ Million), 2020 - 2030
Figure 16 Spain Dilated Cardiomyopathy Therapeutics Market (US$ Million), 2020 - 2030
Figure 17 Italy Dilated Cardiomyopathy Therapeutics Market (US$ Million), 2020 - 2030
Figure 18 France Dilated Cardiomyopathy Therapeutics Market (US$ Million), 2020 - 2030
Figure 19 Rest of Europe Dilated Cardiomyopathy Therapeutics Market (US$ Million), 2020 - 2030
Figure 20 China Dilated Cardiomyopathy Therapeutics Market (US$ Million), 2020 - 2030
Figure 21 Japan Dilated Cardiomyopathy Therapeutics Market (US$ Million), 2020 - 2030
Figure 22 India Dilated Cardiomyopathy Therapeutics Market (US$ Million), 2020 - 2030
Figure 23 Australia Dilated Cardiomyopathy Therapeutics Market (US$ Million), 2020 - 2030
Figure 24 South Korea Dilated Cardiomyopathy Therapeutics Market (US$ Million), 2020 - 2030
Figure 25 Rest of Asia Dilated Cardiomyopathy Therapeutics Market (US$ Million), 2020 - 2030
Figure 26 Brazil Dilated Cardiomyopathy Therapeutics Market (US$ Million), 2020 - 2030
Figure 27 Mexico Dilated Cardiomyopathy Therapeutics Market (US$ Million), 2020 - 2030
Figure 28 Rest of Latin America Dilated Cardiomyopathy Therapeutics Market (US$ Million), 2020 - 2030
Figure 29 GCC Dilated Cardiomyopathy Therapeutics Market (US$ Million), 2020 - 2030
Figure 30 Africa Dilated Cardiomyopathy Therapeutics Market (US$ Million), 2020 - 2030
Figure 31 Rest of Middle East and Africa Dilated Cardiomyopathy Therapeutics Market (US$ Million), 2020 - 2030

List of Tables
Table 1 Global Dilated Cardiomyopathy Therapeutics Market By Treatment, 2020-2030, USD (Million)
Table 2 Global Dilated Cardiomyopathy Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 3 Global Dilated Cardiomyopathy Therapeutics Market By Implantable Device, 2020-2030, USD (Million)
Table 4 North America Dilated Cardiomyopathy Therapeutics Market By Treatment, 2020-2030, USD (Million)
Table 5 North America Dilated Cardiomyopathy Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 6 North America Dilated Cardiomyopathy Therapeutics Market By Implantable Device, 2020-2030, USD (Million)
Table 7 U.S. Dilated Cardiomyopathy Therapeutics Market By Treatment, 2020-2030, USD (Million)
Table 8 U.S. Dilated Cardiomyopathy Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 9 U.S. Dilated Cardiomyopathy Therapeutics Market By Implantable Device, 2020-2030, USD (Million)
Table 10 Canada Dilated Cardiomyopathy Therapeutics Market By Treatment, 2020-2030, USD (Million)
Table 11 Canada Dilated Cardiomyopathy Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 12 Canada Dilated Cardiomyopathy Therapeutics Market By Implantable Device, 2020-2030, USD (Million)
Table 13 Rest of North America Dilated Cardiomyopathy Therapeutics Market By Treatment, 2020-2030, USD (Million)
Table 14 Rest of North America Dilated Cardiomyopathy Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 15 Rest of North America Dilated Cardiomyopathy Therapeutics Market By Implantable Device, 2020-2030, USD (Million)
Table 16 UK and European Union Dilated Cardiomyopathy Therapeutics Market By Treatment, 2020-2030, USD (Million)
Table 17 UK and European Union Dilated Cardiomyopathy Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 18 UK and European Union Dilated Cardiomyopathy Therapeutics Market By Implantable Device, 2020-2030, USD (Million)
Table 19 UK Dilated Cardiomyopathy Therapeutics Market By Treatment, 2020-2030, USD (Million)
Table 20 UK Dilated Cardiomyopathy Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 21 UK Dilated Cardiomyopathy Therapeutics Market By Implantable Device, 2020-2030, USD (Million)
Table 22 Germany Dilated Cardiomyopathy Therapeutics Market By Treatment, 2020-2030, USD (Million)
Table 23 Germany Dilated Cardiomyopathy Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 24 Germany Dilated Cardiomyopathy Therapeutics Market By Implantable Device, 2020-2030, USD (Million)
Table 25 Spain Dilated Cardiomyopathy Therapeutics Market By Treatment, 2020-2030, USD (Million)
Table 26 Spain Dilated Cardiomyopathy Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 27 Spain Dilated Cardiomyopathy Therapeutics Market By Implantable Device, 2020-2030, USD (Million)
Table 28 Italy Dilated Cardiomyopathy Therapeutics Market By Treatment, 2020-2030, USD (Million)
Table 29 Italy Dilated Cardiomyopathy Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 30 Italy Dilated Cardiomyopathy Therapeutics Market By Implantable Device, 2020-2030, USD (Million)
Table 31 France Dilated Cardiomyopathy Therapeutics Market By Treatment, 2020-2030, USD (Million)
Table 32 France Dilated Cardiomyopathy Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 33 France Dilated Cardiomyopathy Therapeutics Market By Implantable Device, 2020-2030, USD (Million)
Table 34 Rest of Europe Dilated Cardiomyopathy Therapeutics Market By Treatment, 2020-2030, USD (Million)
Table 35 Rest of Europe Dilated Cardiomyopathy Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 36 Rest of Europe Dilated Cardiomyopathy Therapeutics Market By Implantable Device, 2020-2030, USD (Million)
Table 37 Asia Dilated Cardiomyopathy Therapeutics Market By Treatment, 2020-2030, USD (Million)
Table 38 Asia Dilated Cardiomyopathy Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 39 Asia Dilated Cardiomyopathy Therapeutics Market By Implantable Device, 2020-2030, USD (Million)
Table 40 China Dilated Cardiomyopathy Therapeutics Market By Treatment, 2020-2030, USD (Million)
Table 41 China Dilated Cardiomyopathy Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 42 China Dilated Cardiomyopathy Therapeutics Market By Implantable Device, 2020-2030, USD (Million)
Table 43 Japan Dilated Cardiomyopathy Therapeutics Market By Treatment, 2020-2030, USD (Million)
Table 44 Japan Dilated Cardiomyopathy Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 45 Japan Dilated Cardiomyopathy Therapeutics Market By Implantable Device, 2020-2030, USD (Million)
Table 46 India Dilated Cardiomyopathy Therapeutics Market By Treatment, 2020-2030, USD (Million)
Table 47 India Dilated Cardiomyopathy Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 48 India Dilated Cardiomyopathy Therapeutics Market By Implantable Device, 2020-2030, USD (Million)
Table 49 Australia Dilated Cardiomyopathy Therapeutics Market By Treatment, 2020-2030, USD (Million)
Table 50 Australia Dilated Cardiomyopathy Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 51 Australia Dilated Cardiomyopathy Therapeutics Market By Implantable Device, 2020-2030, USD (Million)
Table 52 South Korea Dilated Cardiomyopathy Therapeutics Market By Treatment, 2020-2030, USD (Million)
Table 53 South Korea Dilated Cardiomyopathy Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 54 South Korea Dilated Cardiomyopathy Therapeutics Market By Implantable Device, 2020-2030, USD (Million)
Table 55 Latin America Dilated Cardiomyopathy Therapeutics Market By Treatment, 2020-2030, USD (Million)
Table 56 Latin America Dilated Cardiomyopathy Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 57 Latin America Dilated Cardiomyopathy Therapeutics Market By Implantable Device, 2020-2030, USD (Million)
Table 58 Brazil Dilated Cardiomyopathy Therapeutics Market By Treatment, 2020-2030, USD (Million)
Table 59 Brazil Dilated Cardiomyopathy Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 60 Brazil Dilated Cardiomyopathy Therapeutics Market By Implantable Device, 2020-2030, USD (Million)
Table 61 Mexico Dilated Cardiomyopathy Therapeutics Market By Treatment, 2020-2030, USD (Million)
Table 62 Mexico Dilated Cardiomyopathy Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 63 Mexico Dilated Cardiomyopathy Therapeutics Market By Implantable Device, 2020-2030, USD (Million)
Table 64 Rest of Latin America Dilated Cardiomyopathy Therapeutics Market By Treatment, 2020-2030, USD (Million)
Table 65 Rest of Latin America Dilated Cardiomyopathy Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 66 Rest of Latin America Dilated Cardiomyopathy Therapeutics Market By Implantable Device, 2020-2030, USD (Million)
Table 67 Middle East and Africa Dilated Cardiomyopathy Therapeutics Market By Treatment, 2020-2030, USD (Million)
Table 68 Middle East and Africa Dilated Cardiomyopathy Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 69 Middle East and Africa Dilated Cardiomyopathy Therapeutics Market By Implantable Device, 2020-2030, USD (Million)
Table 70 GCC Dilated Cardiomyopathy Therapeutics Market By Treatment, 2020-2030, USD (Million)
Table 71 GCC Dilated Cardiomyopathy Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 72 GCC Dilated Cardiomyopathy Therapeutics Market By Implantable Device, 2020-2030, USD (Million)
Table 73 Africa Dilated Cardiomyopathy Therapeutics Market By Treatment, 2020-2030, USD (Million)
Table 74 Africa Dilated Cardiomyopathy Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 75 Africa Dilated Cardiomyopathy Therapeutics Market By Implantable Device, 2020-2030, USD (Million)
Table 76 Rest of Middle East and Africa Dilated Cardiomyopathy Therapeutics Market By Treatment, 2020-2030, USD (Million)
Table 77 Rest of Middle East and Africa Dilated Cardiomyopathy Therapeutics Market By Drug Class, 2020-2030, USD (Million)
Table 78 Rest of Middle East and Africa Dilated Cardiomyopathy Therapeutics Market By Implantable Device, 2020-2030, USD (Million)

Companies Mentioned

  • Aastrom Biosciences
  • Capricor Therapeutics
  • GlaxoSmithkline Plc
  • Johnson and Johnson
  • Kasiak Research Pvt. Ltd.
  • Merck & Co. Inc.
  • MyoKardia
  • Pfizer Inc.
  • t2cure GmbH
  • Teva Pharmaceutical Industries
  • ZensunSci & Tech.

Related Topics

Related Reports

Global Dilated Cardiomyopathy Therapeutics Market by Drug class, Treatment Type, Route of Administration, End-User, Distribution Channel - Forecast 2024-2030 - Product Image

Global Dilated Cardiomyopathy Therapeutics Market by Drug class, Treatment Type, Route of Administration, End-User, Distribution Channel - Forecast 2024-2030

  • Report
  • 192 Pages
  • Global
From
Global Dilated Cardiomyopathy Market by Drug Class Inhibitors, Treatment Type, Route of Administration, Distribution Channel, and By Region - Product Image

Global Dilated Cardiomyopathy Market by Drug Class Inhibitors, Treatment Type, Route of Administration, Distribution Channel, and By Region

  • Report
  • 200 Pages
  • Global
From
Dilated Cardiomyopathy Therapeutics: Global Strategic Business Report - Product Image

Dilated Cardiomyopathy Therapeutics: Global Strategic Business Report

  • Report
  • 197 Pages
  • Global
From
Dilated Cardiomyopathy Treatment Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Dilated Cardiomyopathy Treatment Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 109 Pages
  • Global
From
Dilated Cardiomyopathy (DCM) - Epidemiology Forecast - 2034 - Product Image

Dilated Cardiomyopathy (DCM) - Epidemiology Forecast - 2034

  • Report
  • 80 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.